Oligometastatic patients with castration-resistant prostate cancer
Conditions
Brief summary
Radiological progression by choline PET/CT or 68Ga-PSMA PET/CT, in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT.
Detailed description
Overall survival (time from initiation of second-generation antiandrogen to exitus) in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT., Quality of life of these patients using the European Organization for Research and Treatment of Cancer (EORTC) quality QLQ-C30, validated for oncology patients. of life scale, EORTC ., Acute and chronic toxicity according to the "Common Terminology Criteria for Adverse Events" (CTCAEv5.0) scale.
Interventions
DRUGAbiraterona Normon 500 mg comprimidos revestidos por película
DRUGXtandi - 80 mg film-coated tablets
Sponsors
Instituto de investigación en Oncología radioterápica FEOR (Fundación Española de Oncología RT)
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiological progression by choline PET/CT or 68Ga-PSMA PET/CT, in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT. | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (time from initiation of second-generation antiandrogen to exitus) in patients with mCRPC treated with the combination of second-generation antiandrogen plus SBRT., Quality of life of these patients using the European Organization for Research and Treatment of Cancer (EORTC) quality QLQ-C30, validated for oncology patients. of life scale, EORTC ., Acute and chronic toxicity according to the "Common Terminology Criteria for Adverse Events" (CTCAEv5.0) scale. | — |
Countries
Spain
Outcome results
None listed